LC Acquisition LLC

LC Acquisition LLC, doing business as Axcend LLC, manufactures liquid chromatography platforms and analytical instrumentation for federal research, development, and medical applications, competing as a prime contractor on full-and-open Navy purchase orders and as a recipient of Small Business Innovation Research (SBIR) grants from the National Institute on Drug Abuse. The Dallas-based for-profit limited liability company holds no SBA certifications across its recent federal footprint and operates without set-aside designation on its defense contracts.

Axcend's concrete capability set centers on compact, portable capillary liquid chromatography systems designed for point-of-care and field-level analytical work. On the prime contract side, the company has delivered a $114,464 firm fixed-price liquid chromatography platform to the Naval Air Warfare Center with delivery by October 2025 and a $61,150 purchase order to the Bureau of Medicine and Surgery in 2024 under contract AX-101002. The company also operates as a subcontractor to Luna Labs USA LLC, providing autosampler device development support on an Air Force SBIR Phase II project for metal deactivator detection in aviation fuels and custom UI development for an automated spectrometry system targeting PTSD biomarkers.

Federal grant work anchors Axcend's recent activity. The National Institute on Drug Abuse funded two SBIR phase projects: a $313,721 Phase I award (effective June 1, 2026, through May 31, 2027) for development of a miniature tandem Ion Mobility Spectrometry detector integrated into the Axcend Focus capillary LC system to detect novel psychoactive substances and fentanyl adulterants in bodily fluids at parts-per-billion sensitivity, and an earlier Phase I/II fast-track award from September 2022 (ultimate completion April 2027) for compact liquid chromatography development targeting point-of-care drug screening in substance use disorder treatment centers. Work is performed in Dallas, Texas.

Customer concentration spans defense medical and research agencies. The Department of the Navy (Naval Air Warfare Center and Bureau of Medicine and Surgery) accounts for $175,000 in combined potential value across two purchase orders, while the National Institute on Drug Abuse holds two SBIR grant awards. The company also serves the Air Force Materiel Command and the Defense Health Agency across its six-award footprint. Activity is sparse but recurring — one award in 2022, three in 2024, and one each in 2025 and 2026 — with two awards (the NIDA Phase I project and the Air Force SBIR sub task) facing ultimate completion within the next twenty-four months. The source reports combined obligated dollars of $7.9 million against a combined potential value of $176,000, indicating significant delivery and invoicing against the SBIR grants.